Physician profile
Madeline Turner
NPI 1063447373
$5,185.21
in general payments reported to CMS, 2019-2025
28 companies · $906 in 2025
The $906 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $392 · 2021: $855 · 2022: $688 · 2023: $898 · 2024: $963 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,598 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,598.32 |
| Education | $167.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,117.74 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $932.91 | 2019-2025 | Aklief, Nemluvio, Twyneo |
| Dermavant Sciences, INC. | $429.87 | 2023-2024 | Vtama |
| Genzyme Corporation | $280.78 | 2019-2025 | |
| Abbvie INC. | $264.78 | 2021-2025 | Botox |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.20 | 2022-2025 | Spevigo |
| Novartis Pharmaceuticals Corporation | $172.73 | 2019-2024 | |
| Journey Medical Corporation | $166.97 | 2019-2025 | |
| Lilly USA, LLC | $152.17 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Epi Health, LLC | $151.87 | 2019-2021 | |
| Pfizer INC. | $137.53 | 2019-2025 | |
| Leo Pharma INC. | $125.98 | 2021-2024 | Adbry |
| Sun Pharmaceutical Industries INC. | $120.00 | 2019-2022 | |
| Almirall LLC | $119.06 | 2019-2024 | Klisyri |
| E.R. Squibb & Sons, L.L.C. | $116.14 | 2023-2024 | Sotyktu |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $104.86 | 2019-2022 | |
| Amgen INC. | $100.84 | 2021-2024 | Otezla |
| Allergan, INC. | $76.71 | 2021-2022 | |
| Encore Dermatology INC. | $70.17 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $64.58 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $60.46 | 2023 | |
| Mayne Pharma Commercial LLC | $43.04 | 2022-2025 | |
| Ucb, INC. | $32.25 | 2024 | |
| Janssen Scientific Affairs, LLC | $27.55 | 2020 | |
| Vyne Pharmaceuticals INC. | $23.69 | 2020-2021 | |
| Biofrontera INC. | $21.58 | 2019 | |
| Incyte Corporation | $16.12 | 2023 | Opzelura |
| Organon LLC | $12.63 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madeline Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.